These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34917611)

  • 1. TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer.
    Zhang Z; Hao R; Guo Q; Zhang S; Wang X
    Front Cell Dev Biol; 2021; 9():759154. PubMed ID: 34917611
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients.
    Cui S; Feng J; Tang X; Lou S; Guo W; Xiao X; Li S; Chen X; Huan Y; Zhou Y; Xiao L
    Eur J Med Res; 2023 Feb; 28(1):90. PubMed ID: 36805828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in
    Wen Y; Ouyang D; Chen Q; Zeng L; Luo N; He H; Anwar M; Qu L; Zou Q; Yi W
    Gland Surg; 2022 Jan; 11(1):100-114. PubMed ID: 35242673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
    Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
    Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
    Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
    PeerJ; 2023; 11():e15654. PubMed ID: 37520246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and
    Li Y; Dong W; Zhang P; Zhang T; Ma L; Qu M; Ma X; Zhou X; He Q
    Front Cell Dev Biol; 2021; 9():750897. PubMed ID: 34733851
    [No Abstract]   [Full Text] [Related]  

  • 10.
    Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
    Front Genet; 2021; 12():762160. PubMed ID: 34795697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer.
    Jiang M; Wu X; Bao S; Wang X; Qu F; Liu Q; Huang X; Li W; Tang J; Yin Y
    Front Immunol; 2022; 13():946468. PubMed ID: 35935965
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
    Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
    Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
    Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
    Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
    Front Oncol; 2022; 12():998336. PubMed ID: 36185230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
    Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
    World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 20. The prognostic value and potential immunotherapeutic efficacy of
    Zhang H; Liu R; Chen Y; Ma R; Xue Q; Sahu A; Yan X; Gu H
    J Gastrointest Oncol; 2024 Feb; 15(1):63-85. PubMed ID: 38482233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.